# CareDx, Inc.: financial statements, quarterly

CDNA · Nasdaq · CIK 1217234 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cdna.md) · [Financials](/companies/cdna/financials.md) · [Filings](/companies/cdna/filings.md) · [Insiders](/companies/cdna/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cdna/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [65.6 d](/filings/0001217234-26-000018.md) | [72.0](/filings/0001217234-25-000037.md) | [92.3](/filings/0001217234-25-000046.md) | [82.9](/filings/0001217234-25-000063.md) | [86.6 d](/filings/0001217234-26-000018.md) | [84.7](/filings/0001217234-26-000033.md) | [86.7](/filings/0001217234-26-000046.md) | [100](/filings/0001217234-26-000061.md) | [108 d](/filings/0001217234-26-000018.md) | [118](/filings/0001217234-26-000033.md) | [132](/filings/0001217234-26-000046.md) | [139](/filings/0001217234-26-000061.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [18.8 d](/filings/0001217234-26-000018.md) | [18.7](/filings/0001217234-25-000037.md) | [19.7](/filings/0001217234-25-000046.md) | [17.5](/filings/0001217234-25-000063.md) | [16.6 d](/filings/0001217234-26-000018.md) | [18.5](/filings/0001217234-26-000033.md) | [16.8](/filings/0001217234-26-000046.md) | [16.8](/filings/0001217234-26-000061.md) | [19.3 d](/filings/0001217234-26-000018.md) | [21.4](/filings/0001217234-26-000033.md) | [22.4](/filings/0001217234-26-000046.md) | [21.3](/filings/0001217234-26-000061.md) |
| Operating income | $m | [(123) d](/filings/0001217234-26-000018.md) | [(22.6)](/filings/0001217234-25-000037.md) | [(7.3)](/filings/0001217234-25-000046.md) | [(13.7)](/filings/0001217234-25-000063.md) | [84.4 d](/filings/0001217234-26-000018.md) | [(13.4)](/filings/0001217234-26-000033.md) | [(11.1)](/filings/0001217234-26-000046.md) | [(0.2)](/filings/0001217234-26-000061.md) | [(6.0) d](/filings/0001217234-26-000018.md) | [1.2](/filings/0001217234-26-000033.md) | [113](/filings/0001217234-26-000046.md) | [8.1](/filings/0001217234-26-000061.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.2 d](/filings/0001217234-26-000018.md) | [(0.1)](/filings/0001217234-25-000037.md) | [0.0](/filings/0001217234-25-000046.md) | [0.2](/filings/0001217234-25-000063.md) | [0.2 d](/filings/0001217234-26-000018.md) | [0.1](/filings/0001217234-26-000033.md) | [(0.1)](/filings/0001217234-26-000046.md) | [(0.0)](/filings/0001217234-26-000061.md) | [0.3 d](/filings/0001217234-26-000018.md) | [(0.0)](/filings/0001217234-26-000033.md) | [3.9](/filings/0001217234-26-000046.md) | [(8.6)](/filings/0001217234-26-000061.md) |
| Net income | $m | [(118) d](/filings/0001217234-26-000018.md) | [(19.9)](/filings/0001217234-25-000063.md) | [(4.6)](/filings/0001217234-25-000063.md) | [(10.6)](/filings/0001217234-25-000063.md) | [87.7 d](/filings/0001217234-26-000018.md) | [(10.4)](/filings/0001217234-26-000061.md) | [(8.6)](/filings/0001217234-26-000061.md) | [1.7](/filings/0001217234-26-000061.md) | [(4.1) d](/filings/0001217234-26-000018.md) | [2.8](/filings/0001217234-26-000061.md) | [111](/filings/0001217234-26-000061.md) | [19.3](/filings/0001217234-26-000061.md) |
| Diluted EPS | $ per share | not reported | [(0.38)](/filings/0001217234-25-000037.md) | [(0.09)](/filings/0001217234-25-000046.md) | [(0.20)](/filings/0001217234-25-000063.md) | not reported | [(0.19)](/filings/0001217234-26-000033.md) | [(0.16)](/filings/0001217234-26-000046.md) | [0.03](/filings/0001217234-26-000061.md) | not reported | [0.05](/filings/0001217234-26-000033.md) | [2.07](/filings/0001217234-26-000046.md) | [0.35](/filings/0001217234-26-000061.md) |
| Basic EPS | $ per share | not reported | [(0.38)](/filings/0001217234-25-000037.md) | [(0.09)](/filings/0001217234-25-000046.md) | [(0.20)](/filings/0001217234-25-000063.md) | not reported | [(0.19)](/filings/0001217234-26-000033.md) | [(0.16)](/filings/0001217234-26-000046.md) | [0.03](/filings/0001217234-26-000061.md) | not reported | [0.05](/filings/0001217234-26-000033.md) | [2.15](/filings/0001217234-26-000046.md) | [0.37](/filings/0001217234-26-000061.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [82.2](/filings/0001217234-26-000018.md) | [93.3](/filings/0001217234-25-000037.md) | [95.8](/filings/0001217234-25-000046.md) | [95.4](/filings/0001217234-25-000063.md) | [115](/filings/0001217234-26-000018.md) | [88.7](/filings/0001217234-26-000033.md) | [68.2](/filings/0001217234-26-000046.md) | [91.4](/filings/0001217234-26-000061.md) | [65.4](/filings/0001217234-26-000061.md) | [77.9](/filings/0001217234-26-000033.md) | [374](/filings/0001217234-26-000046.md) | [250](/filings/0001217234-26-000061.md) |
| Current assets | $m | [314](/filings/0001217234-25-000012.md) | [303](/filings/0001217234-24-000064.md) | [321](/filings/0001217234-24-000083.md) | [334](/filings/0001217234-24-000103.md) | [352](/filings/0001217234-26-000018.md) | [350](/filings/0001217234-25-000037.md) | [307](/filings/0001217234-25-000046.md) | [300](/filings/0001217234-25-000063.md) | [257](/filings/0001217234-26-000061.md) | [269](/filings/0001217234-26-000033.md) | [429](/filings/0001217234-26-000046.md) | [321](/filings/0001217234-26-000061.md) |
| Total assets | $m | [467](/filings/0001217234-25-000012.md) | [452](/filings/0001217234-24-000064.md) | [467](/filings/0001217234-24-000083.md) | [477](/filings/0001217234-24-000103.md) | [491](/filings/0001217234-26-000018.md) | [490](/filings/0001217234-25-000037.md) | [444](/filings/0001217234-25-000046.md) | [432](/filings/0001217234-25-000063.md) | [413](/filings/0001217234-26-000061.md) | [411](/filings/0001217234-26-000033.md) | [533](/filings/0001217234-26-000046.md) | [641](/filings/0001217234-26-000061.md) |
| Current liabilities | $m | [78.1](/filings/0001217234-25-000012.md) | [70.2](/filings/0001217234-24-000064.md) | [78.3](/filings/0001217234-24-000083.md) | [81.4](/filings/0001217234-24-000103.md) | [89.4](/filings/0001217234-26-000018.md) | [85.3](/filings/0001217234-25-000037.md) | [93.2](/filings/0001217234-25-000046.md) | [99.0](/filings/0001217234-25-000063.md) | [89.8](/filings/0001217234-26-000061.md) | [79.2](/filings/0001217234-26-000033.md) | [93.7](/filings/0001217234-26-000046.md) | [139](/filings/0001217234-26-000061.md) |
| Total liabilities | $m | [205](/filings/0001217234-25-000012.md) | [196](/filings/0001217234-24-000064.md) | [202](/filings/0001217234-24-000083.md) | [204](/filings/0001217234-24-000103.md) | [113](/filings/0001217234-26-000018.md) | [110](/filings/0001217234-25-000037.md) | [117](/filings/0001217234-25-000046.md) | [121](/filings/0001217234-25-000063.md) | [110](/filings/0001217234-26-000061.md) | [97.5](/filings/0001217234-26-000033.md) | [107](/filings/0001217234-26-000046.md) | [174](/filings/0001217234-26-000061.md) |
| Long-term debt | $m | not reported | not reported | [0.0](/filings/0001217234-24-000083.md) | [0.0](/filings/0001217234-24-000103.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [261](/filings/0001217234-26-000018.md) | [256](/filings/0001217234-25-000063.md) | [265](/filings/0001217234-25-000063.md) | [273](/filings/0001217234-25-000063.md) | [378](/filings/0001217234-26-000061.md) | [379](/filings/0001217234-26-000061.md) | [327](/filings/0001217234-26-000061.md) | [311](/filings/0001217234-26-000061.md) | [303](/filings/0001217234-26-000061.md) | [314](/filings/0001217234-26-000061.md) | [426](/filings/0001217234-26-000061.md) | [467](/filings/0001217234-26-000061.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.4) d](/filings/0001217234-26-000018.md) | [(15.3)](/filings/0001217234-25-000037.md) | [18.9 d](/filings/0001217234-25-000046.md) | [12.5 d](/filings/0001217234-25-000063.md) | [21.9 d](/filings/0001217234-26-000018.md) | [(26.6)](/filings/0001217234-26-000033.md) | [9.9 d](/filings/0001217234-26-000046.md) | [37.4 d](/filings/0001217234-26-000061.md) | [21.4 d](/filings/0001217234-26-000018.md) | [4.3](/filings/0001217234-26-000033.md) | [30.6 d](/filings/0001217234-26-000046.md) | [12.7 d](/filings/0001217234-26-000061.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | [1.6](/filings/0001217234-26-000033.md) | [1.0 d](/filings/0001217234-26-000046.md) | [1.3 d](/filings/0001217234-26-000061.md) | not reported | [3.8](/filings/0001217234-26-000033.md) | [1.9 d](/filings/0001217234-26-000046.md) | [1.6 d](/filings/0001217234-26-000061.md) |
| Share repurchases | $m | [26.0 d](/filings/0001217234-26-000018.md) | [0.5](/filings/0001217234-25-000037.md) | [0.0 d](/filings/0001217234-25-000046.md) | [0.0 d](/filings/0001217234-25-000063.md) | [0.0 d](/filings/0001217234-26-000018.md) | [0.0](/filings/0001217234-25-000037.md) | [50.0 d](/filings/0001217234-26-000046.md) | [25.6 d](/filings/0001217234-26-000061.md) | [12.2 d](/filings/0001217234-26-000018.md) | not reported | not reported | [0.0 d](/filings/0001217234-26-000061.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [53.6](/filings/0001217234-24-000064.md) | [53.8](/filings/0001217234-24-000083.md) | [54.2](/filings/0001217234-24-000103.md) | [51.7](/filings/0001217234-25-000037.md) | [52.2](/filings/0001217234-25-000046.md) | [52.9](/filings/0001217234-25-000063.md) | [55.3](/filings/0001217234-26-000033.md) | [54.3](/filings/0001217234-26-000046.md) | [53.7](/filings/0001217234-26-000061.md) | [53.1](/filings/0001217234-26-000033.md) | [53.4](/filings/0001217234-26-000046.md) | [55.0](/filings/0001217234-26-000061.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 52,542,786 at 2026-10-26, from the cover of the [10-Q filed 2026-10-29](/filings/0001217234-26-000061.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 16:39 ET. No prices; not investment advice.